Accipiter Biosciences
Seattle, US · Founded 2023 · Delaware corporation · 26 employees on LinkedIn · 4 known investors
Accipiter Biosciences uses computational protein design to develop de novo, single-agent protein therapies that engage multiple cell-surface receptors at once, functioning as agonists. Its platform targets complex conditions such as autoimmune disorders and cancer as an alternative to traditional combination therapies.
Founders & leadership
Accipiter Biosciences was founded in 2023 by Matthew Bick.
MB
Matthew BickinFounder
JC
Javier CastellanosNamed on SEC filing
HD
Hector De Jesus Rincon AranoNamed on SEC filing
HR
Heather RedmanNamed on SEC filing
RS
Randall SchatzmanNamed on SEC filing
WC
William CanestaroNamed on SEC filing
Board
JA
Jose Antonio Mesa CejudoBoard director
HG
Heather GorhamBoard director
JG
Jiaping GuBoard director
Investors · 4
Funding
SEC filings, press & company announcements$37.4M disclosed across 4 rounds · 2023–2026
- $12.7MSeed FinancingNov 2025 · 2 sourcesSource ↗
▶$10.5MraisedJul 2026 · 9 investors · BiotechnologyRule 506(b)
▶$10.5MraisedJul 2026 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Matthew BickExecutive Officer, Director, Promoter
- Hector De Jesus Rincon AranoExecutive Officer, Director, Promoter
- Javier CastellanosExecutive Officer, Director, Promoter
- Heather RedmanDirector
- Randall SchatzmanDirector
- William CanestaroExecutive Officer
- Jose Antonio Mesa CejudoDirector
- Offering amount
- $10.5M
- Amount sold
- $10.5M
- First sale
- Jul 2026
- Incorporated
- Corporation, Delaware, 2023
- Federal exemptions
- 06b
▶$13.6MraisedSep 2025 · 15 investors · Other TechnologyRule 506(b)
▶$13.6MraisedSep 2025 · 15 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Heather GorhamDirector
- Jose Antonio Mesa CejudoDirector
- Jiaping GuDirector
- Matthew BickExecutive Officer, Director, Promoter
- Javier CastellanosExecutive Officer, Director, Promoter
- Hector De Jesus Rincon AranoExecutive Officer, Promoter
- Offering amount
- $13.7M
- Amount sold
- $13.6M
- First sale
- May 2024
- Incorporated
- Corporation, Delaware, 2023
- Federal exemptions
- 06b
▶$650KraisedMay 2023 · 6 investors · Other TechnologyRule 506(b)
▶$650KraisedMay 2023 · 6 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Matthew BickExecutive Officer, Director, Promoter
- William ArthurExecutive Officer, Director, Promoter
- Javier CastellanosExecutive Officer, Director, Promoter
- Hector AranoExecutive Officer, Director, Promoter
- Offering amount
- $1M
- Amount sold
- $650K
- First sale
- Apr 2023
- Incorporated
- Corporation, Delaware, 2023
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 6
by search overlap
IQVIA4 shared keywordsIQVIA provides data, analytics, AI, and technology-driven services for life sciences and healthcare organizations, spanning clinical development, real world evidence generation, and commercial execution. It offers integrated solutions for clinical trials, regulatory and safety compliance, and market analytics, including agentic AI products for commercial and R&D teams.
Kite Pharma3 shared keywordsKite Pharma develops CAR T-cell therapies for cancer patients, engineering the immune system's cells to target and attack cancer. Each therapy is individualized per patient through a multi-step manufacturing process.
Avidity Nanomedicines3 shared keywordsAvidity Biosciences develops Antibody Oligonucleotide Conjugates (AOCs) that combine monoclonal antibody specificity with oligonucleotide precision for targeted delivery of RNA therapeutics to treat rare genetic muscle diseases. The company has three clinical-stage programs targeting myotonic dystrophy type 1, facioscapulohumeral muscular dystrophy, and Duchenne muscular dystrophy.
Aro Biotherapeutics3 shared keywordsAro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins. The company builds a wholly-owned pipeline of Centyrin-based therapeutic candidates and partners with industry to enable tissue-specific targeting of therapeutics across a range of diseases.
Fortis Life Sciences3 shared keywordsFortis Life Sciences develops and manufactures Bethyl-branded ELISA kits and related reagents, buffers, and antibodies for detecting target proteins in research and diagnostic applications. The kits cover human and veterinary targets and are made in the USA using the company's own antibodies.
C4 Therapeutics3 shared keywordsC4 Therapeutics develops targeted protein degradation medicines aimed at treating disease. The company works in the biotechnology and drug development space.
Companies competing with Accipiter Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Moving faster than planned, AI drug developer Accipiter Bio quietly tops up seed round with $10.5M – GeekWiregeekwire.com · Jul 2026Frequently asked questions
- What does Accipiter Biosciences do?
- Accipiter Biosciences uses computational protein design to develop de novo, single-agent protein therapies that engage multiple cell-surface receptors at once, functioning as agonists. Its platform targets complex conditions such as autoimmune disorders and cancer as an alternative to traditional combination therapies.
- Who founded Accipiter Biosciences?
- Accipiter Biosciences was founded by Matthew Bick in 2023.
- Who are Accipiter Biosciences's investors?
- Accipiter Biosciences's investors include Argonautic Ventures, Columbus Venture Partners, Pack Ventures, WRF Capital.
- How much funding has Accipiter Biosciences raised?
- Accipiter Biosciences has disclosed $37.4M raised across 4 rounds.
- Where is Accipiter Biosciences headquartered?
- Accipiter Biosciences is headquartered in Seattle, US.